TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Taysha Gene Therapies, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.94+0.32 (+8.84%)

Close on Oct 19, 2026

Community

Notes and questions about Taysha Gene Therapies from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Taysha Gene Therapies's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TSHA.

Revenue growth-32.3% · median 10.0%

Operating margin-2792.3% · median -2112.1%

Net margin-2728.0% · median -2031.1%

Advertisement
300 × 250